Stock picks with research | support | resistance and technical analysis for trading | Day trading | stock investing in the market

• About US

Market Activity

Premium Plan

Trading Technologies

Day Trading

Stock Trading

Stock Trading Strategy

Technical Strategy

Breakout Stocks

Penny Stock investing

stock Breakout for day trading

Stock : EBS	\| Stock Recommendations : Buy
Sector : Biotech & Drugs	\| First resistance : 18.19
Stock Name : EMERGENT BIOSOLUTIONS INC COM	\| Second resistance :
Buy Near :	\| Third resistance :
StopLoss :	\| First Support : 16.11
Posted date : 11/2/2008 12:00:00 AM	\| Second Support : 14.60

Emergent BioSolutions Inc. com (EBS) Stock has given a buy signal, with rising moving average. Stockhastic and ADX also given a buy signal.

Emergent BioSolutions Inc. com (EBS) announced on 10/1/08, it will receive between $364 million and $404 million for new contracts to supply the U.S. government with anthrax vaccines. Emergent BioSolutions Inc. com (EBS) is a Biotechnology company. As per technical analysis, Stock analysis and fundamentally this Stock looks good candidate for portfolio investment. Emergent BioSolutions Inc. com Stock you can consider for Stock Market Investment, Swing Trading, Stock trading, Stock Investing, Day trading, Stock picks, Breakout Stocks. Due to Stock market and economic condition keep tight stop loss on all position. You can buy this Stock near $18

Portfolio stock

Recent News Head Lines

Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View
(Tue, 14 Jan 2020 15:03:03 +0000)
Emergent (EBS) narrows revenue view for 2019 and expects a consistent rise in Narcan nasal spray sales during 2020.

Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
(Mon, 13 Jan 2020 11:40:10 +0000)
Emergent BioSolutions Inc. (EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed development plan for its chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. The company has proposed conducting a safety and immunogenicity Phase 3 trial using Serum Neutralizing Antibodies (SNA) as an immune correlate of protection to predict clinical benefit of the vaccine candidate.

Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast
(Mon, 13 Jan 2020 11:30:10 +0000)
Full year 2019 preliminary revenues and adjusted profitability metrics in line with prior guidanceFull year 2020 forecast reflects continued growth of core business as well as.

AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down
(Fri, 10 Jan 2020 23:08:11 +0000)
AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.

Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer
(Fri, 10 Jan 2020 15:27:03 +0000)
Blueprint Medicines (BPMC) gets its maiden FDA approval for its lead candidate Ayvakit to treat adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST).

Never go against major trend for day trading | stock trading

Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

All Rights Reserved © 2000-2006 Flyingstock.com
Chart courtesy of StockCharts.com
Portfolio stock - EMERGENT BIOSOLUTIONS INC COM for Stock investing stock trading day trading

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.